IP Library › Granted Patent US 9,072,776
Granted Patent B2
US 9,072,776 · App. 11/917,521 · Granted Jul 7, 2015

Anti-cancer combination treatment and kit-of-parts

Inventor: Bjørn Kristiansen (Frederikstad, NO)
Assignee: Glycanova AS
A61K45/06A61K31/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,072,776
App. No.
11/917,521
Granted
Jul 7, 2015
Kind
B2
Abstract

In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.

Claims (16)

1. A pharmaceutical kit of parts comprising

a) an anti-cancer medicament, and

b) a Basidiomycete bioactive agent, said Basidiomycete being of the genus Lentinus , in solid or liquid form,

wherein said bioactive agent comprises a heteropolymeric polysaccharide comprising the monosaccharide units glucose, galactose and mannose,

wherein said heteropolymeric polysaccharide has a molecular weight in the size range of from 100,000 g/mol to 1,000,000 g/mol,

wherein said bioactive agent is isolated from the liquid growth medium of a liquid culture of the genus Lentinus after the mycelium has been removed from said liquid culture, and

wherein said liquid growth medium is not subjected to alcohol precipitation.

2. The kit according to claim 1 , wherein the bioactive agent is precipitated by ultracentrifugation.

3. The kit according to claim 1 , wherein said anticancer medicament is suitable for administration simultaneously with the administration of the bioactive agent.

4. The kit of claim 1 , further comprising instructions for a dosing regime.

5. The kit of claim 1 , wherein said polysaccharide does not comprise a peptide or a polypeptide.

6. A method of treatment comprising the step of administering the anti-cancer medicament and the bioactive agent of the pharmaceutical kit of parts according to claim 1 to an individual in need thereof according to a set dosage regime.

7. The method of claim 6 , wherein the anti-cancer medicament and the bioactive agent are administered simultaneously.

8. The method of claim 7 , wherein the anti-cancer medicament and the bioactive agent are administered as a co-formulation.

9. The method of claim 6 , wherein the anti-cancer medicament and the bioactive agent are administered sequentially.

10. The kit of claim 1 , wherein the bioactive agent is obtainable from Lentinus edodes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: MEDIMUSH A/S
To: BEKA HOLDING AS
Reel/Frame 031459/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: BEKA HOLDING AS
To: GLYCANOVA AS
Reel/Frame 031460/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2008
From: KRISTIANSEN, BJORN
To: MEDIMUSH A/S
Reel/Frame 021534/0104 →
Priority Claims (2)
DK 2005 00882 · Jun 15, 2005 · national
DK 2006 00116 · Jan 25, 2006 · national
Continuity (3)
Provisional Application 60690482 · Jun 15, 2005
Provisional Application 60761743 · Jan 25, 2006
Related Publication 20090143280A1 · Jun 4, 2009